- Home
- VANI
as 07-26-2024 4:00pm EST
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 73.1M | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 105.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $7.80 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vivani Medical Inc. (DE) (VANI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Williams Gregg | VANI | Director10% Owner | Feb 15 '24 | Buy | $1.01 | 1,078 | $1,088.78 | 727,608 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Feb 8 '24 | Buy | $1.01 | 1,119 | $1,130.19 | 725,459 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Feb 8 '24 | Buy | $1.01 | 1,071 | $1,081.71 | 726,530 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Feb 5 '24 | Buy | $1.01 | 1,939 | $1,958.39 | 724,284 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Feb 5 '24 | Buy | $1.01 | 56 | $56.56 | 724,340 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 31 '24 | Buy | $1.01 | 100 | $101.00 | 722,345 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 23 '24 | Buy | $1.01 | 834 | $842.34 | 722,245 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 22 '24 | Buy | $1.01 | 7,620 | $7,696.20 | 721,411 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 18 '24 | Buy | $1.01 | 999 | $1,008.99 | 713,714 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 18 '24 | Buy | $1.01 | 77 | $77.77 | 713,791 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 16 '24 | Buy | $1.01 | 13,067 | $13,197.67 | 712,715 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 8 '24 | Buy | $1.08 | 6,731 | $7,269.48 | 699,648 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 4 '24 | Buy | $1.07 | 4,200 | $4,494.00 | 690,917 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 4 '24 | Buy | $1.08 | 2,000 | $2,160.00 | 692,917 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 2 '24 | Buy | $1.01 | 3,548 | $3,583.48 | 683,154 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Jan 2 '24 | Buy | $1.01 | 3,563 | $3,598.63 | 686,717 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Dec 22 '23 | Buy | $1.00 | 100 | $100.00 | 679,606 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Dec 19 '23 | Buy | $0.86 | 198 | $170.28 | 525,832 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Dec 19 '23 | Buy | $0.88 | 3,734 | $3,285.92 | 529,566 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Dec 19 '23 | Buy | $0.88 | 149,940 | $131,947.20 | 679,506 | SEC Form 4 |
| Makes Brigid | VANI | CFO | Dec 15 '23 | Buy | $0.89 | 4,000 | $3,560.00 | 14,000 | SEC Form 4 |
| Makes Brigid | VANI | CFO | Dec 15 '23 | Buy | $0.87 | 1,000 | $870.00 | 15,000 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Dec 14 '23 | Buy | $0.88 | 301 | $264.88 | 521,634 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Dec 14 '23 | Buy | $0.89 | 2,000 | $1,780.00 | 523,634 | SEC Form 4 |
| Williams Gregg | VANI | Director10% Owner | Dec 14 '23 | Buy | $0.90 | 2,000 | $1,800.00 | 525,634 | SEC Form 4 |
Latest Vivani Medical Inc. (DE) News
VANI Breaking Stock News: Dive into VANI Ticker-Specific Updates for Smart Investing
Medical Device Network
15 days ago
Vivani to start in-human trial for GLP-1 implant for treating obesity
Business Wire
15 days ago
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
Benzinga
16 days ago
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Exec Edge
a month ago
Vivani Medical Receives FDA Clearance for Trial of Type-2 Diabetes Mini-Implant
MT Newswires
a month ago
Vivani Medical Says US FDA Approved Investigational New Drug Application for Potential Type 2 Diabetes Treatment
Benzinga
a month ago
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's IND Gains FDA Clearance For Clinical Use (UPDATED)
Business Wire
a month ago
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
Simply Wall St.
2 months ago
Insider Stock Buying Reaches US$751.8k On Vivani Medical
Compare VANI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VANI Vivani Medical Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.